SOUTH SAN FRANCISCO, Calif., July 25 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) will announce its second quarter 2005 financial results on Monday, August 8, 2005, after the markets close.

The announcement will be followed by a live webcast at 2:00 p.m. PDT/5:00 p.m. EDT. of a discussion by Exelixis management of second quarter 2005 financial results. The webcast may be accessed in the Events page under Investor Information on the Exelixis website at http://www.exelixis.com .

An archive of this webcast will be available until 9:00 p.m. PDT/12:00 a.m. EDT on August 15, 2005. Access numbers for this replay are: 1-877-660- 6853 (domestic) and 1-201-612-7415 (international); Conference ID number is: 162462.

About Exelixis

Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics across various disease areas. The company is leveraging its fully integrated gene-to- drug platform to fuel the growth of its proprietary drug pipeline. Exelixis' development pipeline covers cancer and metabolism and is comprised of the following compounds: XL119 (becatecarin), for which a multinational Phase III clinical trial in bile duct tumors is ongoing and which has been exclusively licensed to Helsinn Healthcare SA with rights to reacquire commercial rights for North America; XL784, initially an anticancer compound, which completed a Phase I clinical trial and is being advanced as a treatment for renal disease; XL647, XL999, XL880 and XL820, anticancer compounds currently in Phase I clinical trials; XL844 and XL184, anticancer compounds for which INDs have been filed; and multiple compounds in preclinical development for diseases including cancer and various metabolic and cardiovascular disorders. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies including GlaxoSmithKline (GSK) and Bristol-Myers Squibb Company. Pursuant to a product development and commercialization agreement between Exelixis and GSK, GSK has the option, after completion of Phase IIa clinical trials by Exelixis, to elect to develop a certain number of compounds in Exelixis' product pipeline, which may include the cancer compounds identified in this press release (other than XL119), thus potentially triggering milestone payments and royalties from GSK and co- promotion rights by Exelixis. For more information, please visit the company's web site at www.exelixis.com.

SOURCE  Exelixis, Inc.
    -0-                             07/25/2005
    /CONTACT:  Charles Butler, Associate Director, Corporate Communications of
Exelixis, Inc., +1-650-837-7277, or cbutler@exelixis.com/
    /Web site:  http://www.exelixis.com /
    (EXEL)

CO:  Exelixis, Inc.
ST:  California
IN:  MTC BIO HEA
SU:  CCA

HD
-- SFM078 --
7619 07/25/2005 16:10 EDT http://www.prnewswire.com